---
title: "TherapeuticsMD, Inc. (TXMD.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/TXMD.US.md"
symbol: "TXMD.US"
name: "TherapeuticsMD, Inc."
industry: "制藥"
---

# TherapeuticsMD, Inc. (TXMD.US)

| Item | Detail |
|------|--------|
| Industry | 制藥 |
| Location | 美股市場 |
| Website | [www.therapeuticsmd.com](https://www.therapeuticsmd.com) |

## Company Profile

TherapeuticsMD，inc.作為一家制藥公司運營。它側重于婦女產品的開發和商業化。該公司的技術 SYMBODA 開發了先進的激素治療藥物產品，以通過多種劑型和給藥途徑輸送生物相同的激素。它還生產和分銷品牌和通用處方產前維生素，以及 BIJUVA，IMVEXXY，vitaMedMD 和 bocareenmd 品牌下的非處方維生素。該公司由羅伯特·G·菲尼齊奧和布萊恩·A·伯尼克 1907 年創立，總部設在佛羅里達州博卡拉頓。

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-16T04:30:12.000Z

**Overall: B (0.39)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 34 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 75.19% |  |
| Net Profit YoY | 109.11% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.00 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 27.32M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 2.80M |  |


**Multi Score**: B

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.27% | D |
| Profit Margin | 10.80% | B |
| Gross Margin | 100.00% | A |

#### Growth Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 75.19% | A |
| Net Profit YoY | 109.11% | A |
| Total Assets YoY | -2.23% | D |
| Net Assets YoY | 1.29% | C |

#### Cash Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 925.83% | B |
| OCF YoY | 75.19% | A |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.07 | E |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 29.03% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - TherapeuticsMD, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.27%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "10.80%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "A",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "75.19%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "109.11%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-2.23%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "1.29%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "A",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "925.83%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "75.19%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.07",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "29.03%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 禮來 (US.LLY) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B |
| 03 | 羅氏(ADR) (US.RHHBY) | A | B | B | D | C | B |
| 04 | 阿斯利康 (US.AZN) | A | B | C | D | C | B |
| 05 | 諾華制藥 (US.NVS) | A | B | C | D | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 90.45 | 55/256 | 87.77 | 68.99 | 62.85 |
| PB | 1.00 | 44/256 | 0.70 | 0.50 | 0.45 |
| PS (TTM) | 9.77 | 112/256 | 8.15 | 6.92 | 5.38 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2023-08-17T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 0 | 0% |
| Hold | 1 | 100% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.36 |

## References

- [Company Overview](https://longbridge.com/en/quote/TXMD.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/TXMD.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/TXMD.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.